[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ruihua Wei\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,65,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100658053","control-of-myopia-in-young-children-using-hope-lenses-combined-with-002-atropine-eye-drops-100658053",false,"NCT07846787","Control of Myopia in Young Children Using H.O.P.E. Lenses Combined With 0.02% Atropine Eye Drops","A Multicenter, Prospective, Intervention Study on the Control of Myopia in Young Children Using High-order Phase Element Array Microstructure Lenses (H.O.P.E.) in Combination With Low-concentration Atropine Eye Drops (0.02%)","Inclusion Criteria:\n\n1. Age: 6-9 years old (6 years old but under 10 years old), gender not restricted;\n2. Clinically diagnosed with bilateral myopia (after cycloplegia), refractive error within -6.00D \\\u003C SER ≤ -0.50D, astigmatism ≤ 1.50D, refractive anisometropia ≤ 1.50D (based on subjective refraction values);\n3. Corrected visual acuity LogMAR ≤ 0.1;\n4. Able to understand the research purpose, voluntarily participate, and the subject and his\u002Fher legal guardian sign the informed consent form.\n\nExclusion Criteria:\n\nIf a subject meets any of the following exclusion criteria, they will not be included in this study:\n\n1. Those who have discontinued the use of atropine eye drops (due to glaucoma or a tendency towards glaucoma, or are allergic to scopolamine or the components of this product);\n2. Those currently suffering from any of the following diseases that may affect vision or refractive errors, or ocular organic diseases: such as diseases causing damage to the lens like cataracts, glaucoma, macular degeneration, corneal diseases, uveitis, retinal detachment, severe vitreous opacity, acute\u002Fchronic keratitis, conjunctivitis, irregular cornea, keratoconus, manifest strabismus, fundus diseases, etc.; systemic diseases that may affect the eyes, such as immune system diseases, central nervous system diseases, Down syndrome, asthma, epilepsy, severe heart or lung function disorders, severe liver or kidney function impairments, etc.;\n3. Those who have participated in other clinical trials or studies related to myopia control within 90 days before signing the informed consent form;\n4. Those who have used myopia control products within 90 days before signing the informed consent form (such as near-axial lenses, low-concentration atropine eye drops, corneal reshaping lenses, red light, etc.);\n5. Those who cannot wear glasses regularly or use the medication as required (such as having a significant difference in compliance);\n6. During the screening period, the intraocular pressure of either eye is greater than 21 mmHg or less than 10 mmHg, or the intraocular pressure difference between both eyes is ≥ 5 mmHg;\n7. There is a severe abnormality in the accommodative function (accommodative amplitude \\\u003C 8D);\n8. Only one eye meets the inclusion criteria;\n9. Other situations that the researcher deems unsuitable for participating in this study.","ALL","6 Years","9 Years",{"count":20,"type":21},264,"ESTIMATED","INTERVENTIONAL",[24],"NA","A multicenter, prospective, intervention study on the control of myopia in young children using high-order phase element array microstructure lenses (H.O.P.E.) in combination with low-concentration atropine eye drops (0.02%)",[27],"Myopia",[29],"myopia","NOT_YET_RECRUITING","2026-09-22",{"date":33,"type":34},"2026-09-29","ACTUAL",{"date":36,"type":21},"2026-09-30",{"date":38,"type":21},"2028-09-20",{"name":40,"class":41},"Ruihua Wei","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100607248","therapeutic-efficacy-of-different-repeated-low-intensity-red-light-devices-and-different-usage-frequencies-100607248","NCT07186088","Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies","Study on the Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies for Adult Myopia Treatment","Inclusion Criteria:\n\n* 18-35 years old, gender not limited; Obtained informed consent.\n\nExclusion Criteria:\n\n* Obvious strabismus and amblyopia\n* With congenital eye disease, such as congenital cataract, congenital retinal disease\n* Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)\n* Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)\n* Refractive medium opacity (such as corneal disease, crystal opacity, etc.)\n* Bnormal intraocular pressure and clinical significance (IOP \\\u003C10 mmHg or IOP\\>21mmHg or binocular IOP difference ≥5mmHg)\n* Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases\n* Optic nerve damage or congenital optic nerve dysfunction\n* Can not be regularly checked\n* The adjustment range is less than 8D or obvious near difficulties\n* Other reasons researchers think it is not suitable for inclusion in researchers","18 Years","35 Years",{"count":53,"type":21},30,[24],"To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light",[27],"2025-09-15",{"date":59,"type":34},"2025-09-22",{"date":61,"type":21},"2025-09-20",{"date":63,"type":21},"2026-06-20",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":42},"100605247","repeatability-of-ao-slo-mona-iia-technology-and-cone-cell-density-of-individuals-use-repeated-low-level-red-light-therapy-100605247","NCT07160036","Repeatability of AO-SLO (Mona IIa) Technology and Cone Cell Density of Individuals Use Repeated Low-level Red-light Therapy","Exploring the Repeatability of Adaptive Optics Scanning Laser Ophthalmoscope Technology (AO-SLO Mona IIa) and the Differences in Cone Cell Density Between Individuals Who Undergone and Not Undergone Repeated Low-level Red-light","AO-SLO","Inclusion Criteria:\n\n* 6 - 55 years old, gender not limited; Obtained informed consent.\n\nExclusion Criteria:\n\n* Children with obvious strabismus and amblyopia\n* With congenital eye disease, such as congenital cataract, congenital retinal disease\n* Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)\n* Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)\n* Refractive medium opacity (such as corneal disease, crystal opacity, etc.)\n* Bnormal intraocular pressure and clinical significance (IOP \\\u003C10 mmHg or IOP\\>21mmHg or binocular IOP difference ≥5mmHg)\n* Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases\n* Optic nerve damage or congenital optic nerve dysfunction\n* Can not be regularly checked\n* The adjustment range is less than 8D or obvious near difficulties\n* Other reasons researchers think it is not suitable for inclusion in researchers","55 Years",{"count":75,"type":21},180,[24],"To explore the repeatability of AO-SLO (Mona IIa) technology and the difference of cone cell density between individuals who used or not used repeated low-intensity red light treatment",[27],"RECRUITING","2025-09-08",{"date":57,"type":34},{"date":61,"type":21},{"date":84,"type":21},"2025-12-20",{"name":40,"class":41},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":42},"100556315","phase-1-atropine-002-004-combined-with-defocus-dims-for-moderate-and-high-myopia-control-100556315","NCT06523504","Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control","Efficacy and Safety of Low-concentration Atropine Eye Drops (0.02%, 0.04%) Combined With Defocus Incorporated Multiple Segments (DIMS) for Moderate and High Myopia Control","atropine","Inclusion Criteria:\n\n* School-age children aged 6 to 12 years (including boundary value)\n* Children with moderate or high myopia (subjective refraction after cycloplegia: -9.00D≤spherical equivalent (SE)≤-3.00D, with-rule astigmatism (C)≤2.00D, against-rule astigmatism (C)≤1.00D, anisometropia of both eyes≤2.50D)\n* Binocular best corrected visual acuity (BCVA)≥0.8 (five-point visual acuity 4.9)\n* Agree with the study scheme and sign the informed consent\n* Note: if both eyes meet the inclusion criteria, the eye with higher spherical equivalent is the study eye; if one eye meets the inclusion criteria, the eye is the study eye.\n\nExclusion Criteria:\n\n* Used or currently using orthokeratology, multifocal contact lenses, defocusing framework lenses, atropine eye drops and other myopia control means in the past month; used red light treatment in the past\n* Children with obvious strabismus and amblyopia\n* With congenital eye disease, such as congenital cataract, congenital retinal disease\n* Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)\n* Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)\n* Refractive medium opacity (such as corneal disease, crystal opacity, etc.)\n* Bnormal intraocular pressure and clinical significance (IOP \\<10 mmHg or IOP \\>21mmHg or binocular IOP difference ≥5mmHg)\n* Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases\n* Optic nerve damage or congenital optic nerve dysfunction\n* Can not be regularly checked\n* The adjustment range is less than 8D or obvious near difficulties\n* Other reasons researchers think it is not suitable for inclusion in researchers","12 Years",{"count":96,"type":21},410,[98,99],"PHASE1","PHASE2","To evaluate the effectiveness and safety of DIMS, low concentration atropine eye drops,and atropine combined with DIMS in controlling axial length and refraction in children with moderate to high myopia.",[27],"2025-08-30",{"date":80,"type":34},{"date":105,"type":34},"2024-02-01",{"date":107,"type":21},"2026-03-31",{"name":40,"class":41},""]